Physician profile
Aamer Mirza
NPI 1730173857
$7,151.60
in general payments reported to CMS, 2019-2025
35 companies · $1,815 in 2025
The $1,815 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $458 · 2021: $1,005 · 2022: $1,088 · 2023: $901 · 2024: $1,022 · 2025: $1,815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,723 · Education: $14.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,723.37 |
| Education | $14.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,462.17 | 2019-2025 | |
| Janssen Biotech, INC. | $1,125.84 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $890.85 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $882.36 | 2019-2025 | |
| Madrigal Pharmaceuticals | $366.41 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $327.69 | 2020-2025 | |
| Celgene Corporation | $326.44 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $282.57 | 2020-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $185.93 | 2022-2025 | Dupixent |
| Allergan, INC. | $156.12 | 2019-2020 | |
| Boston Scientific Corporation | $151.52 | 2019-2022 | |
| Ardelyx, INC. | $133.80 | 2025 | Ibsrela |
| Medtronic, INC. | $121.63 | 2022 | |
| Janssen Scientific Affairs, LLC | $85.05 | 2024 | Tremfya |
| Daiichi Sankyo INC. | $71.19 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $66.94 | 2023 | Idacio |
| Lilly USA, LLC | $61.98 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $43.28 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $41.56 | 2019 | |
| Ironwood Pharmaceuticals, INC | $41.25 | 2021-2022 | |
| Fujifilm Healthcare Americas Corporation | $40.50 | 2023-2024 | Fujifilm |
| Celltrion USA INC. | $35.97 | 2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $26.32 | 2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $25.47 | 2021 | |
| Ambu INC. | $23.92 | 2022 | |
| Genzyme Corporation | $23.79 | 2022 | |
| Organon LLC | $22.47 | 2023 | Renflexis |
| Braintree Laboratories, INC. | $19.85 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $19.58 | 2025 | |
| Ferring Pharmaceuticals INC. | $17.33 | 2020 | |
| Ucb, INC. | $16.67 | 2019 | |
| Shire North American Group INC | $15.14 | 2019 | |
| Exact Sciences Corporation | $14.10 | 2025 | Cologuard Collection Kit |
| Sandoz INC. | $14.05 | 2023 | Hyrimoz |
| Qol Medical, LLC | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aamer Mirza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.